FI3558280T3 - Migreenin ennaltaehkäisy ja hoito - Google Patents
Migreenin ennaltaehkäisy ja hoito Download PDFInfo
- Publication number
- FI3558280T3 FI3558280T3 FIEP17832224.4T FI17832224T FI3558280T3 FI 3558280 T3 FI3558280 T3 FI 3558280T3 FI 17832224 T FI17832224 T FI 17832224T FI 3558280 T3 FI3558280 T3 FI 3558280T3
- Authority
- FI
- Finland
- Prior art keywords
- symptoms
- salt
- treating
- migraine
- compound according
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title claims 21
- 206010027599 migraine Diseases 0.000 title claims 21
- 230000002265 prevention Effects 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims 20
- 208000024891 symptom Diseases 0.000 claims 19
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 4
- 159000000000 sodium salts Chemical class 0.000 claims 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 239000011575 calcium Substances 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 206010028813 Nausea Diseases 0.000 claims 2
- 150000002576 ketones Chemical class 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 230000008693 nausea Effects 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical class C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims 1
- CSXINIGTBHLAAV-UHFFFAOYSA-N 5,6,7-trihydroxyheptane-2,4-dione Chemical compound CC(=O)CC(=O)C(O)C(O)CO CSXINIGTBHLAAV-UHFFFAOYSA-N 0.000 claims 1
- PFFWDPHBEGSZIL-UHFFFAOYSA-N 5,7-dihydroxyoctane-2,4-dione Chemical compound CC(O)CC(O)C(=O)CC(C)=O PFFWDPHBEGSZIL-UHFFFAOYSA-N 0.000 claims 1
- 208000012639 Balance disease Diseases 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 206010015958 Eye pain Diseases 0.000 claims 1
- 206010016059 Facial pain Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical class NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 206010027940 Mood altered Diseases 0.000 claims 1
- 206010027951 Mood swings Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 206010060860 Neurological symptom Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 206010040026 Sensory disturbance Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 206010072731 White matter lesion Diseases 0.000 claims 1
- -1 acetoacetyl R-3-hydroxybutyrate Chemical compound 0.000 claims 1
- 125000002339 acetoacetyl group Chemical group O=C([*])C([H])([H])C(=O)C([H])([H])[H] 0.000 claims 1
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical class NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 231100000749 chronicity Toxicity 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical class NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 229940042126 oral powder Drugs 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 230000035922 thirst Effects 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16206018 | 2016-12-21 | ||
| EP17154258 | 2017-02-01 | ||
| PCT/EP2017/083880 WO2018115158A1 (en) | 2016-12-21 | 2017-12-20 | Migraine prevention and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3558280T3 true FI3558280T3 (fi) | 2023-07-13 |
Family
ID=61005774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17832224.4T FI3558280T3 (fi) | 2016-12-21 | 2017-12-20 | Migreenin ennaltaehkäisy ja hoito |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11166928B2 (https=) |
| EP (2) | EP4245368A3 (https=) |
| JP (2) | JP7514457B2 (https=) |
| KR (1) | KR102610870B1 (https=) |
| CN (1) | CN110087642B (https=) |
| AU (2) | AU2017384625B2 (https=) |
| CA (1) | CA3046415A1 (https=) |
| DK (1) | DK3558280T3 (https=) |
| ES (1) | ES2948609T3 (https=) |
| FI (1) | FI3558280T3 (https=) |
| HR (1) | HRP20230851T1 (https=) |
| HU (1) | HUE062536T2 (https=) |
| LT (1) | LT3558280T (https=) |
| PL (1) | PL3558280T3 (https=) |
| RU (1) | RU2753057C9 (https=) |
| SI (1) | SI3558280T1 (https=) |
| WO (1) | WO2018115158A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| FI3558280T3 (fi) * | 2016-12-21 | 2023-07-13 | Univ Kinderspital Beider Basel | Migreenin ennaltaehkäisy ja hoito |
| US20180177753A1 (en) | 2016-12-23 | 2018-06-28 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for migraine symptom management |
| US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
| AU2020246928B2 (en) * | 2019-03-22 | 2025-05-15 | Société des Produits Nestlé S.A. | Methods using administration of medium chain triglycerides (MCT) prior to a meal to increase ketone production from the MCTs |
| AU2020274805A1 (en) | 2019-05-10 | 2021-10-28 | Ketoswiss Ag | Ketone bodies enclosed in microbeads |
| EP3956282A1 (de) * | 2019-06-12 | 2022-02-23 | IOI Oleo GmbH | Verfahren zur herstellung von acylverkappten 3-hydroxycarbonsäuren sowie deren salzen und estern |
| CN114008014B (zh) * | 2019-06-12 | 2024-03-22 | 凯托利皮克斯治疗有限责任公司 | 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法 |
| US12396974B2 (en) | 2020-03-27 | 2025-08-26 | KetoneAid | Ketone ester as a therapeutic treatment of Covid-19 and related viral infections |
| CN117677383A (zh) | 2021-07-17 | 2024-03-08 | 瑞士凯托股份公司 | 酮体或生酮化合物与镇痛剂或抗氧化剂的组合 |
| WO2023166069A1 (en) | 2022-03-02 | 2023-09-07 | N.V. Nutricia | Fatty acids for ketosis control |
| CN115590963A (zh) * | 2022-07-13 | 2023-01-13 | 复旦大学（Cn） | 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用 |
| KR102775899B1 (ko) | 2023-12-19 | 2025-02-28 | 한림대학교 산학협력단 | 삽화성 편두통 및 만성 편두통 진단을 위한 정보제공 방법, 장치 및 컴퓨터 프로그램 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0174979A4 (en) * | 1984-03-01 | 1987-11-23 | Vernon Erk | METHOD FOR LOWERING THE BLOOD GLUCOSE LEVEL IN VERBELTIES. |
| JPH0665458A (ja) | 1992-08-21 | 1994-03-08 | Nippon Oil & Fats Co Ltd | 塩素含有樹脂組成物 |
| US5420335A (en) * | 1993-09-30 | 1995-05-30 | Birkhahn; Ronald H. | Parenteral nutrients based on watersoluble glycerol bisacetoacetates |
| CN1315473C (zh) * | 1997-03-17 | 2007-05-16 | 英国技术集团国际有限公司 | 治疗组合物 |
| DK1123094T3 (da) | 1998-09-15 | 2007-08-20 | Btg Int Ltd | Terapeutiske præparater (II) |
| US20050129783A1 (en) * | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
| US7807718B2 (en) * | 2006-06-30 | 2010-10-05 | Sami A. Hashim | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| US20120034193A1 (en) | 2009-01-24 | 2012-02-09 | Daryl Rees | Treatment of neurotrophic factor mediated disorders |
| GB201206192D0 (en) | 2012-04-05 | 2012-05-23 | Tdeltas Ltd | Ketone bodies and ketone body esters and for maintaining or improving muscle power output |
| CN103877118A (zh) | 2014-03-11 | 2014-06-25 | 天津金耀集团有限公司 | 一种由醋丙甲泼尼龙、氧化锌组成的药物组合物 |
| US20160078782A1 (en) * | 2014-09-17 | 2016-03-17 | The Trustees Of Boston College | Glucose Ketone Index for MetabolicTherapy |
| US20180200220A1 (en) * | 2015-07-10 | 2018-07-19 | Cognate Nutritionals, Inc. | Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources |
| FI3558280T3 (fi) * | 2016-12-21 | 2023-07-13 | Univ Kinderspital Beider Basel | Migreenin ennaltaehkäisy ja hoito |
| US20180177753A1 (en) | 2016-12-23 | 2018-06-28 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for migraine symptom management |
| US10500182B2 (en) | 2018-01-10 | 2019-12-10 | Robert Firger | Compositions of ketogenic sources, micronutrients and phytochemicals for prophylaxis and mitigation of migraine headache |
-
2017
- 2017-12-20 FI FIEP17832224.4T patent/FI3558280T3/fi active
- 2017-12-20 SI SI201731394T patent/SI3558280T1/sl unknown
- 2017-12-20 JP JP2019534680A patent/JP7514457B2/ja active Active
- 2017-12-20 DK DK17832224.4T patent/DK3558280T3/da active
- 2017-12-20 ES ES17832224T patent/ES2948609T3/es active Active
- 2017-12-20 HU HUE17832224A patent/HUE062536T2/hu unknown
- 2017-12-20 RU RU2019122562A patent/RU2753057C9/ru active
- 2017-12-20 CA CA3046415A patent/CA3046415A1/en active Pending
- 2017-12-20 EP EP23176972.0A patent/EP4245368A3/en active Pending
- 2017-12-20 AU AU2017384625A patent/AU2017384625B2/en active Active
- 2017-12-20 EP EP17832224.4A patent/EP3558280B1/en active Active
- 2017-12-20 HR HRP20230851TT patent/HRP20230851T1/hr unknown
- 2017-12-20 PL PL17832224.4T patent/PL3558280T3/pl unknown
- 2017-12-20 US US16/472,309 patent/US11166928B2/en active Active
- 2017-12-20 CN CN201780079158.4A patent/CN110087642B/zh active Active
- 2017-12-20 LT LTEPPCT/EP2017/083880T patent/LT3558280T/lt unknown
- 2017-12-20 KR KR1020197021346A patent/KR102610870B1/ko active Active
- 2017-12-20 WO PCT/EP2017/083880 patent/WO2018115158A1/en not_active Ceased
-
2021
- 2021-06-01 US US17/335,319 patent/US11890264B2/en active Active
-
2022
- 2022-03-07 AU AU2022201565A patent/AU2022201565B2/en active Active
- 2022-08-18 JP JP2022130419A patent/JP2022166218A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022201565A1 (en) | 2022-03-31 |
| RU2753057C9 (ru) | 2021-09-10 |
| ES2948609T3 (es) | 2023-09-14 |
| RU2019122562A3 (https=) | 2021-01-27 |
| RU2019122562A (ru) | 2021-01-27 |
| HUE062536T2 (hu) | 2023-11-28 |
| KR20190099486A (ko) | 2019-08-27 |
| KR102610870B1 (ko) | 2023-12-06 |
| CA3046415A1 (en) | 2018-06-28 |
| CN110087642B (zh) | 2022-12-27 |
| EP4245368A3 (en) | 2024-01-03 |
| US11890264B2 (en) | 2024-02-06 |
| AU2022201565B2 (en) | 2023-07-06 |
| CN110087642A (zh) | 2019-08-02 |
| HRP20230851T1 (hr) | 2023-11-10 |
| EP3558280A1 (en) | 2019-10-30 |
| US20190374490A1 (en) | 2019-12-12 |
| JP2020504746A (ja) | 2020-02-13 |
| WO2018115158A1 (en) | 2018-06-28 |
| DK3558280T3 (da) | 2023-08-21 |
| JP7514457B2 (ja) | 2024-07-11 |
| RU2753057C2 (ru) | 2021-08-11 |
| EP4245368A2 (en) | 2023-09-20 |
| AU2017384625B2 (en) | 2021-12-16 |
| JP2022166218A (ja) | 2022-11-01 |
| US11166928B2 (en) | 2021-11-09 |
| LT3558280T (lt) | 2023-10-10 |
| AU2017384625A1 (en) | 2019-06-13 |
| US20210338618A1 (en) | 2021-11-04 |
| PL3558280T3 (pl) | 2023-10-16 |
| EP3558280B1 (en) | 2023-06-07 |
| SI3558280T1 (sl) | 2023-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3558280T3 (fi) | Migreenin ennaltaehkäisy ja hoito | |
| JP2020504746A5 (https=) | ||
| AU765038B2 (en) | Method for the treatment of insomnia | |
| EP2468271B1 (en) | Pharmaceutical composition comprising droxidopa for the treatment of fibromyalgia | |
| EP2986113A1 (en) | Compositions and methods for the treatment of brain injury | |
| JP6060742B2 (ja) | 外用液体組成物 | |
| Jost et al. | Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease | |
| JP2016027026A (ja) | 外用剤 | |
| JP2019137695A (ja) | 皮膚有効成分の浸透方法 | |
| EP1393725B1 (en) | Compositions for ameliorating attention-deficient/hyperactivity disorder | |
| CA2903000C (en) | Methods of improving tolerability, pharmacodynamics, and efficacy of .beta.-alanine and use therefor | |
| US20130224169A1 (en) | Composition and method for recovery from mild traumatic brain injury | |
| US20180147175A1 (en) | Compositions and methods for treatment of movement disorders | |
| VESPIGNANI | Integrative Approaches to Multiple Sclerosis | |
| MX2008010394A (es) | Tratamientos antivirales intravenosos. | |
| Gmiro et al. | Comparison of the Antiparkinson Activity of Levodopa, Memantine, and Guanidine-Containing Analogs of Amantadine and Memantine (IEM-2151 and IEM-2163) in Rats with Rotenone-Induced Parkinsonism | |
| Gmiro et al. | Comparison of the Chronic Anticonvulsant Activity and Safety of IEM-2062, Sodium Valproate, and Memantine in a Corasol Kindling Model in Rats | |
| MXPA00011509A (en) | Method for the treatment of insomnia |